Fabry Disease Market Epidemiology, Size, Trends, and Forecast 2025-2035
The 7 major fabry disease markets reached a value of USD 1,637.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,898.0 Million by 2035, exhibiting a growth rate (CAGR) of 8.20% during 2025-2035.
In 2025, the Fabry disease market is experiencing notable developments, primarily driven by innovations in enzyme replacement therapies (ERT) and gene therapy. Traditional treatment methods have revolved around ERT, with medications like agalsidase beta and agalsidase alfa being widely used to replace the missing enzyme. These therapies help manage the symptoms and delay complications but require lifelong infusions and often come with high costs. One of the key trends in 2025 is the trend towards more efficient and convenient treatment methods. Chaperone treatments are being considered more and more because they treat patients by stabilizing the patient's current enzymes to make them work better. Oral chaperone treatment, Migalastat, has become more popular because of ease of use and good outcomes in specific patient populations with amenable mutations. The oral medication convenience is revolutionizing the patient experience and enhancing treatment adherence.
Gene therapy is another important development that is changing the Fabry disease market. In 2025, numerous candidates in gene therapy are in development and some have reached later-stage clinical trials. Gene therapies promise a single treatment for the underlying cause of the disease by introducing a working copy of the GLA gene into the cells of the patient. If it succeeds, gene therapy might curtail or avoid the necessity of lifelong therapy, dramatically improving the prognosis for Fabry patients. Better diagnostic methods are also contributing to the growth of the market. Genetic screening devices are becoming more available, enabling earlier diagnosis in symptomatic and asymptomatic patients. This is particularly significant since early treatment is crucial to avoiding permanent damage to large organs. Family screening and newborn screening programs are being extended in most areas, assisting in identifying patients before symptoms arise.
Request for a sample of this report: https://www.imarcgroup.com/fabry-disease-market-report/requestsample
Time Period of the Study
Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the fabry disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the fabry disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current fabry disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=30204&flag=
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
